International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers. / Mueller, Jennifer J.; Lajer, Henrik; Mosgaard, Berit Jul; Bach Hamba, Slim; Morice, Philippe; Gouy, Sebastien; Hussein, Yaser; Soslow, Robert A.; Schlappe, Brooke A.; Zhou, Qin C.; Iasonos, Alexia; Høgdall, Claus; Leary, Alexandra; O'Cearbhaill, Roisin E.; Abu-Rustum, Nadeem R.
I: International Journal of Gynecological Cancer, Bind 28, Nr. 5, 2018, s. 915-924.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers
AU - Mueller, Jennifer J.
AU - Lajer, Henrik
AU - Mosgaard, Berit Jul
AU - Bach Hamba, Slim
AU - Morice, Philippe
AU - Gouy, Sebastien
AU - Hussein, Yaser
AU - Soslow, Robert A.
AU - Schlappe, Brooke A.
AU - Zhou, Qin C.
AU - Iasonos, Alexia
AU - Høgdall, Claus
AU - Leary, Alexandra
AU - O'Cearbhaill, Roisin E.
AU - Abu-Rustum, Nadeem R.
PY - 2018
Y1 - 2018
N2 - Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes. Methods This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed. Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy - 55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%-85%) for patients with stage I to II disease and 17% (95% CI, 8%-29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%-86%) for patients who underwent fertility-preserving surgery. Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.
AB - Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes. Methods This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed. Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy - 55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%-85%) for patients with stage I to II disease and 17% (95% CI, 8%-29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%-86%) for patients who underwent fertility-preserving surgery. Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.
KW - Fertility preservation
KW - Ovarian cancer
KW - Primary mucinous ovarian cancer
KW - Survival
U2 - 10.1097/IGC.0000000000001263
DO - 10.1097/IGC.0000000000001263
M3 - Journal article
C2 - 29561302
AN - SCOPUS:85047969394
VL - 28
SP - 915
EP - 924
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 5
ER -
ID: 220861242